SURMOUNT-4 trial results

Adults with overweight or obesity without diabetes who completed a 36-week tirzepatide lead-in.

Mounjaro

Randomised withdrawal trial. Treatment-regimen analysis starts after 36 weeks of tirzepatide.

Mean body weight change from week 36 to week 88

Mean body weight change from week 36 to week 88
Trial arm	Result
Continued tirzepatide 10 or 15 mg	−5.5%
Switched to placebo	+14.0%

Participants who retained at least 80% of lead-in weight loss at week 88
Trial arm	Result
Continued tirzepatide 10 or 15 mg	89.5%
Switched to placebo	16.6%

Safety. Gastrointestinal events were the most common adverse events, generally mild or moderate, and more frequent in the tirzepatide group.